Armata pharmaceuticals, inc. ARMP.US Overview
ARMP AI Analysis & Strategy
Browsing restrictions can be lifted for a fee.
ARMP Current Performance
-1.23%
Armata pharmaceuticals, inc.
-0.91%
Avg of Sector
-0.13%
S&P500
ARMP Key Information
ARMP Revenue by Segments
Browsing restrictions can be lifted for a fee.
ARMP Net Income
Browsing restrictions can be lifted for a fee.
ARMP Cash Flow
Browsing restrictions can be lifted for a fee.
ARMP Profit Margin
Browsing restrictions can be lifted for a fee.
ARMP PE Ratio River
Browsing restrictions can be lifted for a fee.
ARMP Financial Forecast
Browsing restrictions can be lifted for a fee.
| Quarterly | EPS Forecast | QoQ | Max | Min |
|---|---|---|---|---|
| 2025Q1 | ||||
| 2025Q2 | ||||
| 2025Q3 | ||||
| 2025Q4 | ||||
| 2026Q1 |
ARMP Earnings Table
Unit : USD
| QTR | Non-GAAP EPS | EPS YoY | EPS Surprise % | Sales | Sales YoY | Sales Surprise % | NPM |
|---|---|---|---|---|---|---|---|
| Current | |||||||
| 2024Q4 | |||||||
| 2024Q3 | |||||||
| 2024Q2 | |||||||
| 2024Q1 |
ARMP Profile
Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has a partnership agreement with Merck & Co. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Marina del Rey, California.
Price of ARMP
ARMP FAQ
When is ARMP's latest earnings report released?
The most recent financial report for Armata pharmaceuticals, inc. (ARMP) covers the period of 2025Q1 and was published on 2025/03/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating ARMP's short-term business performance and financial health. For the latest updates on ARMP's earnings releases, visit this page regularly.
How is ARMP's revenue growth?
In the latest financial report, Armata pharmaceuticals, inc. (ARMP) announced revenue of 0, with a Year-Over-Year growth rate of -100%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.
How much debt does ARMP have?
As of the end of the reporting period, Armata pharmaceuticals, inc. (ARMP) had total debt of 134.66M, with a debt ratio of 1.54. Short-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.
How much cash does ARMP have?
At the end of the period, Armata pharmaceuticals, inc. (ARMP) held Total Cash and Cash Equivalents of 17.08M, accounting for 0.2 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
Is ARMP's EPS continuing to grow?
According to the past four quarterly reports, Armata pharmaceuticals, inc. (ARMP)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.18. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
What is the FCF of ARMP?
Armata pharmaceuticals, inc. (ARMP)'s Free Cash Flow (FCF) for the period is -7.68M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 29.12% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.